• Cerenome appointed Ron Andrews as chief business officer, a newly created position.
• Andrews will focus on expanding adoption of the CNSide diagnostics platform and developing strategic partnerships.
• He brings more than 35 years of diagnostics leadership experience, including CEO roles at Clarient and Oncocyte.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cerenome Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-455816), on November 12, 2026, and is solely responsible for the information contained therein.